Want to see TNDM full AI Analyst Report?
TNDM Stock Chart & Stats
$21.37
$0.05(0.29%)
At close: 4:00 PM EDT
$21.37
$0.05(0.29%)
Day’s Range― - ―
52-Week Range$11.46 - $29.65
Previous Close$17.17
Volume1.58M
Average Volume (3M)1.87M
Market Cap
$1.27B
Enterprise Value$1.32K
Total Cash (Recent Filing)$456.00M
Total Debt (Recent Filing)$739.25M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 04, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding69,578,705
10 Day Avg. Volume1,182,939
30 Day Avg. Volume1,866,046
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.46Price Target Upside23.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueTandem’s installed pump base supports repeat consumables revenue after the initial hardware sale. Required replenishment can increase customer lifetime value, improve revenue visibility, and create an ecosystem benefit as users remain connected to Tandem’s products and software.
Improving Margins And ProfitabilityGross-margin expansion and four consecutive quarters of positive adjusted EBITDA indicate meaningful operating improvement. If sustained, better unit economics and cost discipline can help Tandem convert revenue growth into durable profitability and reduce dependence on external funding.
Product And Technology ExpansionTandem is broadening its product and technology platform beyond its existing pump offering. Tubeless development, broader CGM interoperability, and the AdaNet algorithm program could strengthen adoption, address more patient needs, and support longer-term competitive relevance.
Bears Say
Elevated LeverageThe thin equity cushion and sharply higher leverage reduce financial flexibility while Tandem remains loss-making. Debt obligations can constrain investment, increase sensitivity to operating setbacks, and make it harder for the company to self-fund product development or absorb weaker demand.
Negative Free Cash Flow And UnprofitabilityTandem’s improving results have not yet produced sustainable earnings or internally generated cash. Negative free cash flow means investment needs still exceed cash generation, while ongoing losses limit resilience and could restrict the company’s ability to fund growth without additional financing.
Tubeless Competitive PressureNew tubeless entrants may intensify competition in a strategically important growth segment. Tandem must execute the Mobi launch and secure clearance on schedule to defend adoption; delays or weaker differentiation could pressure market share, pricing, and future recurring supplies revenue.
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $11.46 and its highest was $29.65 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.27B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Aug 06, 2026. The company reported -$0.307 earnings per share for the quarter, beating the consensus estimate of -$0.321 by $0.014.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.24.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 69,578,705 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.307 in its last earnings report, beating expectations of -$0.321. Following the earnings report the stock price went up 19.106%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.46 (23.84% Upside)
$26.46 (23.84% Upside)
Blogger Sentiment
Neutral
TNDM Sentiment 50%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 994.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TNDM Company Deck
TNDM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: record quarterly sales and shipments, strong international growth, notable gross margin expansion, improving profitability, and clear product and pipeline milestones (Mobi tubeless filing, AdaNet IDE). Near-term challenges include infusion set supplier constraints, a temporary revenue headwind and margin variability from the pharmacy PayGo transition, distributor destocking, and the need to accelerate U.S. new-starts in H2 to meet guidance. On balance, the positives — sizable revenue and margin improvements, product launches, and early PayGo traction — outweigh the near-term operational headwinds, with the company reiterating full-year guidance.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International

TNDM Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$26.46
▲(23.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.00% Insiders
21.52% Mutual Funds
42.89% Other Institutional Investors
8.66% Public Companies and
Individual Investors









